Gazzard BG. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008

Chelsea and Westminster Hospital, Foundation Trust, London, UK.
HIV Medicine (Impact Factor: 3.45). 11/2008; 9(8):563-608. DOI: 10.1111/j.1468-1293.2008.00636.x
Source: PubMed
Download full-text


Available from: Jane Anderson, Aug 20, 2015
  • Source
    • "Patients have the option to continue clinical care either at central or regional levels. Provision of therapy is governed by the National HIV/AIDS Treatment and Care guidelines developed based on the protocols of WHO as well as the guidelines of major Western countries [13] [14] [15] [16]. The first guidelines were developed in 2004 and have been regularly updated thereafter. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since 2004, Georgia achieved universal access to free antiretroviral therapy (ART). A retrospective cohort study was conducted to evaluate the outcomes of Georgia's ART program. The study included adult patients enrolled in the ART program from 2004 through 2009. Of 752 patients, 76% were men, 60% were injection drug users (IDU), 59% had a history of an AIDS-defining illness, and 53% were coinfected with hepatitis C. The median baseline CD4 cell count was 141 cells/mm(3). During followup, 152 (20%) patients died, with the majority of deaths occurring within 12 months of ART initiation. Mortality was associated with advanced immunodeficiency or the presence of incurable disease at baseline. Among patients remaining on treatment, the median CD4 gain was 216 cell/mm(3) and 86% of patients had viral load <400 copies/ml at the last clinical visit. The Georgia ART program has been successful in treating injection drug users infected with HIV.
    AIDS research and treatment 02/2011; 2011:621078. DOI:10.1155/2011/621078
  • Source
    • "HAART comprises the combined use of three or more anti-HIV drugs. The current recommended first line of treatment is a NNRTI, efavirenz, with the nucleoside backbone Truvada ® (emtricitabine and tenofovir disoproxil fumarate) and Kivexa ® (abacavir and lamivudine) (Gazzard, 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The advent of highly active antiretroviral therapy (HAART), which constitutes HIV protease inhibitors, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors, has dramatically reduced the morbidity and mortality associated with human immunodeficiency virus (HIV) infection in resource-rich countries. However, this disease still kills several million people each year. Though the reason for therapeutic failure is multi-factorial, an important concern is the treatment and control of HIV within the central nervous system (CNS). Due to the restricted entry of anti-HIV drugs, the brain is thought to form a viral sanctuary site. This not only results in virological resistance, but also is often associated with the development of complications such as HIV-associated dementia. The CNS delivery of anti-HIV drugs is limited by the blood-brain and blood-CSF interfaces due to a combination of restricted paracellular movement, powerful metabolic enzymes and numerous transporters including members of the ATP binding cassette (ABC) and solute carrier (SLC) superfamilies. A better appreciation of the transporters present at the brain barriers will prove a valuable milestone in understanding the limited brain penetration of anti-HIV drugs in HIV and also aid the development of new anti-HIV drugs and drug combinations, with enhanced efficacy in the CNS. This review aims to summarise current knowledge on the transport of anti-HIV drugs across the blood-brain barrier and the choroid plexus, as well as provide recommendations for future research.
    Antiviral research 02/2009; 82(2):A99-109. DOI:10.1016/j.antiviral.2008.12.013 · 3.94 Impact Factor
  • Source
Show more